



CS/NSE&BSE/BM/2018-19  
March 9, 2019

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**  
**Stock Code: SUVEN–EQ**

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**  
**Stock Code: 530239**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

.....

With reference to the above subject, pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 9th March, 2019, has taken on record the following matters:

1. Approved the creation of Wholly Owned Subsidiary (WOS) Suven Pharma, Inc a Delaware Company in USA under CRAMS Division.
2. Approved investment of 75 Mn USD in the said WOS for new business opportunities and acquisitions etc.,

This is for your information and record.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read "K Hanumantha Rao".

**K Hanumantha Rao**  
Company Secretary

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)